Daniel C. Martin - Jan 18, 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Jan 18, 2022
Transactions value $
$0
Form type
4
Date filed
1/20/2022, 04:00 PM
Previous filing
Dec 17, 2021
Next filing
Feb 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award $0 +13.7K +37.81% $0.00 49.8K Jan 18, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +54.7K $0.00 54.7K Jan 18, 2022 Common Stock 54.7K $8.27 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was awarded 13,667 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock. The RSUs shall vest in three (3) equal annual installments on each of January 15, 2023, January 15, 2024 and January 15, 2025.
F2 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022.